Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CStone Pharmaceuticals
  6. Summary
    2616   KYG2588M1006

CSTONE PHARMACEUTICALS

(2616)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
14.26 14.3 14.78 14.36 14 Last
9960400 9179500 4733500 3366500 4712968 Volume
-9.97% +0.28% +3.36% -2.84% -2.51% Change
Estimated financial data (e)
Sales 2021 265 M 41,0 M 41,0 M
Net income 2021 -1 808 M -280 M -280 M
Net cash position 2021 1 610 M 249 M 249 M
P/E ratio 2021 -10,2x
Yield 2021 -
Sales 2022 1 014 M 157 M 157 M
Net income 2022 -1 523 M -236 M -236 M
Net cash position 2022 1 758 M 272 M 272 M
P/E ratio 2022 -11,2x
Yield 2022 -
Capitalization 16 191 M 2 083 M 2 506 M
EV / Sales 2021 55,0x
EV / Sales 2022 14,2x
Nbr of Employees 470
Free-Float 84,1%
More Financials
Company
CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market. 
More about the company
Ratings of CStone Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CSTONE PHARMACEUTICALS
07/26GENETRON : Says CDx Diagnostic Test Kit Now Under Priority Review, Approval Proc..
MT
07/26GENETRON : AYVAKIT« (avapritinib) Companion Diagnostic Test Enters Priority Revi..
AQ
07/23EQS-ADHOC : HBM Healthcare Investments Quarterly Report June 2021
DJ
07/08CSTONE PHARMACEUTICALS : Pharma Presents Clinical Trial Data at Oncology Confere..
MT
07/07CSTONE PHARMACEUTICALS : announces China NMPA acceptance of IND application for ..
AQ
07/06CSTONE PHARMACEUTICALS : Chinese Regulators Accept CStone Pharma's Clinical Tria..
MT
07/06CStone Announces China NMPA Acceptance of IND Application for CS2006/NM21-148..
CI
06/27CStone Pharmaceuticals Announces Positive Registrational Study of GAVRETO« (p..
CI
06/24CSTONE PHARMACEUTICALS : Pharma to Submit Application for New Use of Cancer Drug..
MT
06/22OPKO Health to Develop and Commercialize RAYALDEE in Greater China with Nicoy..
AQ
06/22BLUEPRINT MEDICINES : CStone Announces First Prescriptions of Precision Therapy ..
AQ
06/21CStone Pharmaceuticals Announces GAVRETO (Pralsetinib) Issued Across Guangdon..
CI
06/15CSTONE PHARMACEUTICALS : Pfizer to Work Together to Develop Lung Cancer Drug in ..
MT
05/28EQRx, along with its partner CStone Pharmaceuticals Announces Phase 3 Study o..
CI
05/28CSTONE PHARMACEUTICALS : Pharma's Lung Cancer Drug Trial Reaches Endpoint; Share..
MT
More news
News in other languages on CSTONE PHARMACEUTICALS
07/23EQS-ADHOC : HBM Healthcare Investments Quartalsbericht Juni 2021
More news
Chart CSTONE PHARMACEUTICALS
Duration : Period :
CStone Pharmaceuticals Technical Analysis Chart | 2616 | KYG2588M1006 | MarketScreener
Technical analysis trends CSTONE PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 14,00 CNY
Average target price 14,37 CNY
Spread / Average Target 2,66%
EPS Revisions
Managers and Directors
Ning Jun Jiang Chairman & Chief Executive Officer
Jian Xin Yang Chief Medical Officer & Senior Vice President
Xin Zhong Wang Chief Scientific Officer & Senior Vice President
Ting Yuk Wu Independent Non-Executive Director
Hong Bin Sun Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CSTONE PHARMACEUTICALS38.89%2 137
GILEAD SCIENCES, INC.17.22%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.36.10%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-14.71%52 296